FDA approved the Farapulse system use, and the company anticipates further regulatory approvals in Europe and Japan. Analysts are bullish on the stock.
2 reports, 1 independent
Updated Jul 15
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved the Farapulse system use, and the company anticipates further regulatory approvals in Europe and Japan. Analysts are bullish on the stock.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- FDA granted expanded labeling approval for Boston Scientific's PFA System, with the company anticipating further regulatory approvals in Japan and China.Sub-event
FDA approved Farapulse system use; anticipates further regulatory approvals in Europe and Japan.1 source
Keep exploring
The entities involved
- FDA
-
Boston Scientific
worldwide developer, manufacturer and marketer of medical devices
-
Europe
terrestrial continent located in north-western Eurasia
Related events
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- FDA and Pfizer are seeking regulatory approval for their products.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- FDA approval enables commercial opportunity involving CBRE Group.
Coverage
Newest first; wire copies grouped- Insider MonkeyBoston Scientific Corp (BSX) Secures FDA Labeling Expansion for FARAPULSE Pulsed Field Ablation (PFA) System Boston Scientific Corporation (NYSE:BSX) is one of Goldman Sachs’ top healthcare stock pic
- Unknown outlet